Literature DB >> 18436327

Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26.

Zhiqing Pang1, Wei Lu, Huile Gao, Kaili Hu, Jun Chen, Chaolin Zhang, Xiaoling Gao, Xinguo Jiang, Cuiqing Zhu.   

Abstract

A novel drug carrier for brain delivery, poly(ethyleneglycol)-poly(epsilon-caprolactone) (PEG-PCL) polymersomes conjugated with mouse-anti-rat monoclonal antibody OX26 (OX26-PO), was developed and its brain delivery property was evaluated. The diblock copolymers of methoxy-PEG-PCL and Maleimide-PEG-PCL were synthesized and applied to prepare polymersomes (PO) which were verified by direct cryogenic temperature transmission electron micrograph (Cryo-TEM) imaging. The TEM examination and dynamic light scattering results showed that OX26-PO had a round and vesicle-like shape with a mean diameter around 100 nm. Coupling of OX26 with PO was confirmed by immuno-gold labeling of OX26 visualized under the TEM and X-ray photoelectron spectroscopy test. The surface OX26 densities were obtained from enzyme-linked immunosorbant assay. The result of brain delivery in rats proved that the increase of surface OX26 density of OX26-PO decreased blood AUC. The optimized OX26 number conjugated per polymersome was 34, which can acquire the greatest blood-brain barrier (BBB) permeability surface area product and percentage of injected dose per gram brain (%ID/g brain). Furthermore, NC-1900, as a model peptide, was encapsulated into OX26(34)-PO and improved the scopolamine-induced learning and memory impairments in a water maze task via i.v. administration. These results indicated that OX26(34)-PO is a promising carrier for peptide brain delivery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18436327     DOI: 10.1016/j.jconrel.2008.03.007

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  48 in total

1.  In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™.

Authors:  Wubeante Yenet Ayen; Neeraj Kumar
Journal:  Pharm Res       Date:  2012-06-06       Impact factor: 4.200

Review 2.  Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.

Authors:  I M Carvalho; P B Coelho; P C Costa; C S Marques; R S Oliveira; D C Ferreira
Journal:  Neuromolecular Med       Date:  2015-09-15       Impact factor: 3.843

Review 3.  Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.

Authors:  Iason T Papademetriou; Tyrone Porter
Journal:  Ther Deliv       Date:  2015-08-25

4.  In vitro and initial in vivo evaluation of (68)Ga-labeled transferrin receptor (TfR) binding peptides as potential carriers for enhanced drug transport into TfR expressing cells.

Authors:  Carmen Wängler; Dina Nada; Georg Höfner; Simone Maschauer; Björn Wängler; Stephan Schneider; Esther Schirrmacher; Klaus T Wanner; Ralf Schirrmacher; Olaf Prante
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

Review 5.  Penetration of the blood-brain barrier by peripheral neuropeptides: new approaches to enhancing transport and endogenous expression.

Authors:  M R Lee; R D Jayant
Journal:  Cell Tissue Res       Date:  2018-12-10       Impact factor: 5.249

Review 6.  Perspectives on Dual Targeting Delivery Systems for Brain Tumors.

Authors:  Huile Gao
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-08       Impact factor: 4.147

7.  EILDV-conjugated, etoposide-loaded biodegradable polymeric micelles directing to tumor metastatic cells overexpressing α4β1 integrin.

Authors:  Mukesh Ukawala; Tushar Rajyaguru; Kiran Chaudhari; A S Manjappa; R S R Murthy; Rajiv Gude
Journal:  Cancer Nanotechnol       Date:  2011-09-15

Review 8.  Imaging of cells and nanoparticles: implications for drug delivery to the brain.

Authors:  Katica Stojanov; Inge S Zuhorn; Rudi A J O Dierckx; Erik F J de Vries
Journal:  Pharm Res       Date:  2012-07-18       Impact factor: 4.200

Review 9.  Polymersome-based drug-delivery strategies for cancer therapeutics.

Authors:  Tayebeh Anajafi; Sanku Mallik
Journal:  Ther Deliv       Date:  2015

10.  Engineering Polymersome Protocells.

Authors:  Neha P Kamat; Joshua S Katz; Daniel A Hammer
Journal:  J Phys Chem Lett       Date:  2011-07-07       Impact factor: 6.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.